About this trial
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- In situ cutaneous microdevice
- Triamcinolone
- 5-Fluorouracil
- Calcipotriene
- Tapinarof
- Crisaborole
- Tacrolimus
- Adalimumab
- Etanercept
- Certolizumab
- Infliximab
- Secukinumab
- Ixekizumab
- Apremilast
- Risankizumab
- Ustekinumab
- Hydroxychloroquine
- Methotrexate
- Mycophenolate
- Azathioprine
- Chloroquine
- Cyclosporine
- Tofacitinib
- Deucravacitinib
- Dupilumab
- Tralokinumab
- Guselkumab
- Tildrakizumab
- Baractinib
- Abrocitinib
- Upadacitinib
- Lebrikizumab
- Nemolizumab
- Ruxolitinib
- Bimekizumab
- Roflumilast